Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07070115 · ClinicalTrials.gov registry record · NA

Evaluating Clinical Hiatal Hernia Outcomes Using OviTex®

A NA study of Hiatal Hernia, sponsored by Tela Bio.

Recruiting
Registry status
NA
Development phase
173
Enrollment target
2
Study locations

NCT07070115: Recruiting NA study of Hiatal Hernia, sponsored by Tela Bio.

NCT07070115 is a NA study of Hiatal Hernia that is actively recruiting participants, run by Tela Bio. The registered enrollment target is 173 participants, below the 871-participant average among 9 other Hiatal Hernia trials with a reported enrollment target (80% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07070115, a NA study of Hiatal Hernia, is actively recruiting participants, sponsored by Tela Bio.

RECRUITING
Registry status
NA
Development phase
173 participants
Enrollment target
2
Study locations

Study Summary

This study will evaluate hiatal hernia recurrence rate and post-operative complications following the use of OviTex Core Resorbable or OviTex 1S Resorbable.

Primary Outcome

Incidence of radiographic recurrence at 24 months, defined as \> 2cm above the hiatus via barium swallow.

Conditions Studied

Interventions

  • DEVICE OviTex Reinforced Tissue Matrix

Study Locations (2)

Alabama

  • University of South Alabama Health - Mobile

Texas

  • The University of Texas at Austin - Dell Medical School - Austin

Trial Details

FieldValue
Enrollment Target 173 participants
Start Date 2025-07-25
Est. Completion 2032-07-31
Phase NA
Tela Bio

5 total trials

What NCT07070115 shows while recruiting

NCT07070115 is an interventional study that assigns participants to a tested intervention. The registered 173 participants enrollment target is mid-sized for trials with a published cap, below the 871-participant average among 9 other Hiatal Hernia trials with a reported enrollment target (80% lower).

The record links to 1 condition, with Hiatal Hernia appearing as the primary indexed condition, and to 1 intervention - of which OviTex Reinforced Tissue Matrix is the first listed.

NCT07070115 reports a single indexed study location in Alabama, Texas.

Frequently Asked Questions

What is clinical trial NCT07070115 about?

NCT07070115 is a clinical study titled "Evaluating Clinical Hiatal Hernia Outcomes Using OviTex®". This study will evaluate hiatal hernia recurrence rate and post-operative complications following the use of OviTex Core Resorbable or OviTex 1S Resorbable.

What is the current status of trial NCT07070115?

This trial is currently recruiting. It is a NA study. The enrollment target is 173 participants. The study started on 2025-07-25. Estimated completion is 2032-07-31.

What conditions does trial NCT07070115 study?

This clinical trial studies the following conditions: Hiatal Hernia.

What interventions are being tested in trial NCT07070115?

The interventions under investigation include: OviTex Reinforced Tissue Matrix (DEVICE).

Who is sponsoring clinical trial NCT07070115?

This trial is sponsored by Tela Bio, which has 5 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07070115 being conducted?

This trial has 2 study locations across Alabama, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Hiatal Hernia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT07070115's enrollment target sits among peer trials

173 3rd of 9 higher than 7 of 9 other Hiatal Hernia trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Hiatal Hernia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT05568719 · 173 participants · Phase 3

    Safety and Effectiveness of Giroctocogene Fitelparvovec or Fidanacogene Elaparvovec in Patients With Hemophilia A or B Respectively

  • NCT07150832 · 173 participants · NA

    Efficacy of the I-CARE Digital Health Intervention

  • NCT01000259 · 174 participants

    Study of Tumor Tissue Samples From Patients Who Have Undergone Surgery for Advanced Stage III or Stage IV Ovarian Epithelial Cancer

  • NCT04729114 · 174 participants · Phase 1

    A Safety and Dose-finding Study of PRL-02 Depot in Men With Advanced Prostate Cancer

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT07070115, the US trial registry maintained by the National Library of Medicine. NCT07070115 (mid enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.